Kura Oncology, Inc. (KURA)
| Market Cap | 646.74M -25.2% |
| Revenue (ttm) | 77.23M -7.3% |
| Net Income | -296.78M |
| EPS | -3.36 |
| Shares Out | 88.96M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,087,653 |
| Open | 6.91 |
| Previous Close | 6.80 |
| Day's Range | 6.75 - 7.40 |
| 52-Week Range | 6.75 - 13.90 |
| Beta | 0.53 |
| Analysts | Strong Buy |
| Price Target | 31.85 (+338.1%) |
| Earnings Date | Nov 10, 2026 |
About KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional n... [Read more]
Financial Performance
In 2025, Kura Oncology's revenue was $67.48 million, an increase of 25.24% compared to the previous year's $53.88 million. Losses were -$278.67 million, 60.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for KURA stock is "Strong Buy." The 12-month stock price target is $31.85, which is an increase of 338.10% from the latest price.
News
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced...
Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026
– Two oral presentations to feature first ziftomenib combination data with quizartinib in newly diagnosed and gilteritinib in relapsed/refractory NPM1/FLT3 co-mutated AML –
Kura Oncology to Report Third Quarter Financial Results on November 10
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced it will report ...
Kura Oncology Transcript: Investor update
Preclinical studies linked KO-7246 to beta-cell expansion, improved glucose control and persistent functional effects after treatment stopped. Caspian is advancing the candidate toward clinical entry, with safety, exposure and stimulated C-peptide among the initial priorities.
Kura Oncology Press release: Investor update
Kura Oncology issued a press release on October 13, 2026, disclosing material business information to investors.
Kura Oncology Slides: Investor update
Kura Oncology has posted slides in relation to its latest quarterly earnings report, which was published on October 13, 2026.
Kura Oncology, Caspian outline KO-7246 development strategy in diabetes
Caspian Therapeutics and Kura Oncology (KURA) announced that they plan to outline the development strategy for KO-7246, Caspian’s selective, oral menin inhibitor designed for diabetes and other chroni...
Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes
– EASD findings support clinical evaluation of a next-generation oral menin inhibitor designed to restore insulin-producing capacity – – IND-enabling development underway to support Phase 1 clinical p...
Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian's Launch and KO-7246 Preclinical Data in Diabetes
– Webcast scheduled for October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT – – Webcast scheduled for October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT –
Kura Oncology initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Kura Oncology (KURA) with an Overweight rating and $30 price target The firm believes Komzifti provides a “floor” for the shares with potential upside from darlifarnib.
Kura Oncology’s KO-7246 shows positive results as menin inhibitor in diabetes
Caspian Therapeutics announced comprehensive preclinical data supporting KO-7246 as a potential best-in-class menin inhibitor for diabetes. KO-7246 regenerated functional beta-cell mass, demonstrated ...
Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes
– KO-7246 regenerated functional β - cell mass and produced durable glycemic control in Type 1 and Type 2 diabetes models –
Kura Oncology Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
KOMZIFTI has rapidly achieved market leadership in relapsed refractory NPM1 mutant AML, driven by strong efficacy, safety, and combinability, with growth expected as it moves into frontline settings. Two phase III trials are on track, darlifarnib advances in kidney and pancreatic cancer, and key milestones are anticipated through 2028.
Kura Oncology Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
KOMZIFTI is rapidly gaining market share in acute leukemia, supported by strong efficacy, safety, and payer access. Multiple phase III trials and data updates are underway, with expansion into diabetes and solid tumors through new ventures and partnerships.
Kura Oncology launches Caspian Therapeutics
Kura Oncology (KURA) announced the launch of Caspian Therapeutics, a separately financed company established to advance small-molecule menin inhibitors for diabetes and cardiometabolic diseases. Caspi...
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes
– $50 million financing led by BVF Partners with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura Oncology, members of the Kura leadership team, and multiple, successful ...
Kura Oncology Transcript: Wells Fargo 21st Annual Healthcare Conference
KOMZIFTI's commercial launch is strong, with rapid revenue growth, broad market access, and majority share in its target population. Multiple late-stage studies are progressing, with key data readouts and regulatory milestones expected through 2028, while pipeline assets in oncology and diabetes advance toward pivotal studies.
Kura Oncology appoints Jennifer Fulk as CFO
Kura Oncology (KURA) announced the appointment of Jennifer Fulk as CFO, effective September 8. Fulk will join Kura’s senior leadership team and report to Troy Wilson, president, CEO and chairman…
Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer
– Seasoned public company CFO with deep biopharmaceutical finance experience across commercial operations, R&D portfolio management, investor relations, and capital allocation – SAN DIEGO, Sept. 08, ...
Kura Oncology to Participate in Three Investor Conferences in September
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that managemen...
Kura Oncology CEO buys $1.24M in common stock
In a regulatory filing, Kura Oncology (KURA) disclosed that its CEO Troy Wilson bought 100K shares of common stock on August 24th in a total transaction size of $1.11M. Shares…
Kura Oncology CEO buys $1.11M in common stock
In a regulatory filing, Kura Oncology (KURA) disclosed that its CEO Troy Wilson bought 100K shares of common stock on August 17th in a total transaction size of $1.11M. Shares…
Kura Oncology reports Q2 EPS (77c), consensus (88c)
Reports Q2 revenue $20.87M, consensus $20.18M. “In only its second full quarter of launch, KOMZIFTI established early leadership in relapsed or refractory NPM1-mutant AML, achieving a majority share o...
Kura Oncology price target raised to $31 from $30 at BofA
BofA raised the firm’s price target on Kura Oncology (KURA) to $31 from $30 and keeps a Buy rating on the shares. Kura’s Q2 was “a win,” says the analyst,…
Kura Oncology Earnings Call Transcript: Q2 2026
KOMZIFTI achieved majority share of new patient starts in relapsed/refractory NPM1-mutated AML, generating $9.1M in revenue and expanding adoption, while darlifarnib showed strong clinical promise in solid tumors. Cash and collaboration revenue are expected to fund key programs through 2028.